1. Home
  2. |Insights
  3. |DoD's Own Cyber Monday Deal: Releasing DFARS Cyber Enhancement Guidance

DoD's Own Cyber Monday Deal: Releasing DFARS Cyber Enhancement Guidance

Client Alert | 1 min read | 11.27.18

Just in time for the holidays, the Defense Department published final guidance to the DoD acquisition community that details strategies to enhance existing cybersecurity requirements for Covered Defense Information (CDI) provided by the DFARS Safeguarding Clause 252.204-7012. The DoD’s guidance contains two documents that clarify how DoD will communicate their cybersecurity expectations to contractors, including where those expectations exceed what the DFARS Safeguarding Clause requires:

  • Guidance for Reviewing System Security Plans (SSPs) outlines how the DoD expects to evaluate contractor SSPs, including the preferred method of meeting each NIST security control and the anticipated consequences of not yet having implemented those controls.
  • Guidance for Assessing Compliance and Enhancing Protections provides objectives that requiring activities can tailor to assess contractors’ safeguarding of CDI, including how to incorporate compliance with NIST SP 800-171 and supply chain management as evaluation criteria in solicitations.

Insights

Client Alert | 3 min read | 06.26.25

FDA Targets Gene Editing Clinical Trials in China and other “Hostile Countries”

In a somewhat ambiguous press release on Wednesday, June 18, 2025, the Food and Drug Administration (FDA) announced a halt and “immediate review” of new clinical trials where American patients’ cells are sent to China or other “hostile countries” for genetic engineering with the expectation that the cells will be infused back into U.S. patients.[1] A subsequent podcast published by the agency also said that therapies that involved cells that were sent to China for genetic engineering and intended for subsequent infusion into U.S. patients would not be approved going forward. The announcement said that there is “mounting evidence” that some clinical researchers failed to obtain informed consent from trial participants about the international transfer and manipulation of biological material....